News Release

Stanford researchers study alcohol, nicotine, Donepezil effects on pilots

Peer-Reviewed Publication

Stanford Medicine

STANFORD, Calif. - Researchers at Stanford University Medical Center and the Veterans Affairs Palo Alto Health Care System have found that pilots who take nicotine or an Alzheimer's disease drug called donepezil fly better than those in a control group, while those who have consumed alcohol are impaired when flying.

Martin Mumenthaler, PhD, a senior research scientist in the Department of Psychiatry and Behavioral Sciences at the School of Medicine, analyzed results of previous trials done over a 10-year period on the effects of alcohol, nicotine and donepezil on pilots. The trials, conducted at the Stanford Aviation Safety Laboratory, focused on how the various drugs affected pilot skill in a flight simulator. Results appear in the July issue of the journal Neuropsychopharmacology.

In the nicotine trials, pilots were given either nicotine gum or a placebo before flying in a simulator that mimicked a single-engine propeller plane. Pilots in the donepezil trial took the drug or a placebo for 30 days between two simulator flights. (Donepezil is normally prescribed to help Alzheimer's patients function better.) Pilots in the alcohol portion of the trial drank either four alcoholic drinks or four placebo drinks. They took one test flight immediately after drinking, when their blood alcohol level was about one-tenth of 1 percent, and another test flight eight hours after their last drink.

Pilots given nicotine or donepezil flew better in the simulator than the control group in their respective trials. Pilots who flew immediately after drinking, however, did much worse in the simulator. Eight hours later, the flight performance of the pilots in the alcohol group was still significantly worse than the performance of the pilots in the control group. Also, pilots on nicotine or donepezil were better at the same flight tasks, especially on approach to landing. "Pilots are getting tired at that point and landing requires a high amount of sustained attention," Mumenthaler said. "That's where the drug benefits them most."

Nicotine and donepezil both affect the cholinergic system of the brain, which is involved in human cognition, Mumenthaler said. The degree of the drugs' similar effects surprised him, however, because they work in different ways. Acetylcholine, the main neurotransmitter in the cholinergic system, binds to nicotinic receptors. Nicotine works just like acetylcholine, directly binding to these receptors. Donepezil, on the other hand, works indirectly by inhibiting the metabolism of acetylcholine. People with fewer nicotinic receptors may be less able to pay attention, learn and remember; patients with Alzheimer's disease may have fewer of these receptors, Mumenthaler said.

Mumenthaler cautioned that pilots shouldn't rely on nicotine or donepezil to improve their flying. Nicotine is addictive and "donepezil can make people dizzy and cause nausea," he said. "You wouldn't want to be up in the air and have those side effects even if they're rare."

Several researchers in the Aviation Safety Laboratory are also pilots, Mumenthaler said. The head of the lab, Jerome Yesavage, MD, professor of psychiatry and behavioral sciences, is a licensed commercial pilot. Mumenthaler, who is licensed for recreational flying, takes the simulator on the occasional spin himself. "But nobody smokes here," he said. The study, he added, is not pro-smoking despite its findings on nicotine's effects.

The findings have inspired additional research on nicotine and flying. Now that smoking is prohibited on most commercial flights, pilots who smoke have to endure without cigarettes. On a flight across the Atlantic or Pacific, that could mean more than 12 hours without nicotine - a long haul for an addict. Mumenthaler said pilots who smoke might chew nicotine gum or wear a nicotine patch to help them on such long flights.

###

The Aviation Safety Laboratory is now recruiting pilots who are smokers for a study on the effects of nicotine withdrawal on flight performance. Prospective volunteers can contact Lisa Wilson at wilsonla@stanford.edu or call 650-493-5000, ext. 66040. The nicotine withdrawal study is being funded by California cigarette taxes through the Tobacco-Related Disease Research Program.

Print media contact: Michelle Brandt, 650-723-0272 (mbrandt@stanford.edu)
Broadcast media contact: Neale Mulligan, 650-724-2454 (nealem@stanford.edu)

Stanford University Medical Center integrates research, medical education and patient care at its three institutions - Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children's Hospital at Stanford. For more information, please visit the Web site of the medical center's Office of Communication & Public Affairs at http://mednews.stanford.edu.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.